Enveric Biosciences Inc ENVB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
-
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
-
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
-
Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003
-
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
Trading Information
- Previous Close Price
- $1.52
- Day Range
- $1.44–1.49
- 52-Week Range
- $1.17–13.25
- Bid/Ask
- $1.45 / $1.48
- Shares Outstanding
- 4.48M
- Market Cap
- $6.61M
- Volume/Avg
- 34,259 / 102,096
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
- Website
- https://www.enveric.com
Valuation
|
Metric
|
ENVB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.74 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ENVB
Financial Strength
|
Metric
|
ENVB
|
|---|---|
Quick Ratio | 9.63 |
Current Ratio | 10.21 |
Interest Coverage | −15,286.30 |
Quick Ratio
ENVB
Profitability
|
Metric
|
ENVB
|
|---|---|
Return on Assets (Normalized) | −147.21% |
Return on Equity (Normalized) | −176.12% |
Return on Invested Capital (Normalized) | −176.11% |
Return on Assets
ENVB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!$t#<!> | LOCK|&>%L& | $128B | |||
| Moderna Inc
MRNA
| LOCK|#G$F$K | LOCK|Yr | $79B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!&^<#G | LOCK|^<^Wl | $76B | |||
| argenx SE ADR
ARGX
| LOCK|@C?@y$^ | LOCK|#w@ | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|zY>FK@r | LOCK|^! | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#L>xM% | LOCK|lgdmr | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|T@v^D<## | LOCK|gWk% | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|#R#w^?P | LOCK|?tn | $23B | |||
| Incyte Corp
INCY
| LOCK|tM@%%T | LOCK|Dg$ | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|QsNM!@^ | LOCK|cl | $14B |
United States